The differentiation of renal from bladder bacteriuria is difficult on clinical grounds alone. To evaluate the correlation between site of infection and urinary beta-glucuronidase activity, 46 patients with well documented recurrent bacteriuria were studied by bilateral ureteral catheterization. Urinary beta-glucuronidase activity was also determined in 46 control subjects. In general, asymptomatic patients with renal bacteriuria, either unilateral or bilateral, had levels of enzyme activity in their urine comparable to patients with infection confined to the bladder and to normals. Only 4 of 25 patients with renal bacteriuria had significant elevations of urinary beta-glucuronidase. After localization of infection, 9 of 10 patients treated with kanamycin, a potentially nephrotoxic drug, developed significant elevations of urinary beta-glucuronidase. The results of these studies indicate that determination of beta-glucuronidase activity in urine is not useful in predicting the site of infection in patients with bacteriuria but may find a role in screening for early nephrotoxicity.
The differentiation of renal from bladder bacteriuria is difficult on clinical grounds alone. To evaluate the correlation between site of infection and urinary beta-glucuronidase activity, 46 patients with well documented recurrent bacteriuria were studied by bilateral ureteral catheterization. Urinary beta-glucuronidase activity was also determined in 46 control subjects. In general, asymptomatic patients with renal bacteriuria, either unilateral or bilateral, had levels of enzyme activity in their urine comparable to patients with infection confined to the bladder and to normals. Only 4 of 25 patients with renal bacteriuria had significant elevations of urinary beta-glucuronidase. After localization of infection, 9 of 10 patients treated with kanamycin, a potentially nephrotoxic drug, developed significant elevations of urinary beta-glucuronidase. The results of these studies indicate that determination of beta-glucuronidase activity in urine is not useful in predicting the site of infection in patients with bacteriuria but may find a role in screening for early nephrotoxicity.
The differentiation of renal from bladder bacteriuria is difficult on clinical grounds alone, especially in the asymptomatic patient. Since recognitition of renal involvement may be useful not only in defining groups of patients for epidemiological and therapeutic studies, but also for guiding the duration and intensity of treatment in an individual patient, an accurate method for localizing the site of urinary tract infection is needed.
In the past, several laboratory tests, which have included selective staining of the urinary sediment (12) , and observation of the sediment after intravenous administration of bacterial pyrogen (9) or adrenal corticosteroid (8) have been employed to distinguish between upper and lower urinary tract infection. In addition, measurements of 0-specific hemagglutinating and other antibody titers (2, 3) and of maximal concentrating ability (13) have also been proposed as methods for differentiating renal involvement in chronic bacteriuria.
Although these procedures may be helpful in characterizing groups of patients, none is specific in individual patients, and to date only bilateral ureteral catheterization has been shown to localize infection with relative certainty (14, 15) .
However, ureteral catheterization cannot be justified for the routine evaluation of patients with recurrent bacteriuria, and there has been a continued search for less cumbersome methods of localizing infection.
Because beta-glucuronidase is found in high concentrations in the mammalian kidney (10) and can be readily assayed in the urine, this enzyme has been studied as a possible indicator of parenchymal renal disease. For example, Bank and Bailine (1) found concentrations of betaglucuronidase elevated in the urine of patients with active pyelonephritis but not in patients with bladder infection. A limitation of these earlier studies has been the definition of the site of urinary tract infection based primarily upon clinical parameters rather than upon precise localization within the urinary tract. The purpose of the present study was to define the urinary activity of beta-glucuronidase in a group of patients with recurrent or persistent bacteriuria in whom the site of infection was localized by ureteral catheterization.
MATERIALS AND METHODS
Forty-six patients, 44 women and 2 men, with well documented recurrent infections of the urinary tract were studied by cystoscopy and bilateral ureteral catheterization employing urological and bacteriological techniques described previously from this laboratory (15 (Fishman units) were divided by the urine creatinine (milligrams per milliliter) to correct for variations in urine volume and to allow comparison with urine samples collected randomly from 46 normal control subjects without bacteriuria. This enzyme-creatinine ratio is expressed as units of betaglucuronidase activity and correlates well with the total enzyme excretion for the 24-hr period (7) .
RESULTS
The results of beta-glucuronidase activity determined in 21 patients with bladder bacteriuria, 25 patients with unilateral or bilateral renal bacteriuria, and 46 normal individuals are summarized in Fig. 1 . The mean beta-glucuronidase activity in the urine of 46 control subjects was 5.1 -1 2.9 units with the accepted upper limit of normal (99% confidence limit) at 13.5 units. This did not differ significantly from the activities in urine of patients with bladder bacteriuria (6.6 i 3.1 units) or renal bacteriuria (8.7 -:-5.3 units). Although not depicted, 14 patients with unilateral renal bacteriuria had levels of activity in their urine comparable to 11 patients with bilateral involvement. Furthermore, the activity in urine from the infected side in patients with unilateral infection did not differ significantly from the activity in the noninfected side. Although four patients with renal bacteriuria (three with unilateral and one with bilateral infection) did demonstrate activity in their urine above 13.5 units, two of these patients had diabetic glomerulosclerosis, one had a renal calculus, and one was found to have a bladder carcinoma in addition to upper tract bacteriuria.
In contradistinction to the lack of correlation between the site of bacteriuria and elevated urinary enzyme activity, iniation of therapy with kanamycin did result in a prompt rise in urinary beta-glucuronidase activity in 9 of 10 patients treated with this potentially nephrotoxic drug. The elevation of beta-glucuronidase in the urine of patients with "active" kidney disease has been attributed to liberation of the enzyme from lysosomes of injured renal tubular cells. It is of interest that after localization of infection 9 of 10 patients in our study did develop significant elevations of this enzyme in their urine during treatment with kanamycin, a potentially nephrotoxic drug, whereas elevations were not detected in patients receiving other antimicrobials. The elevation in enzyme activity was most marked at the onset of kanamycin therapy and returned to initial levels promptly upon cessation of treatment. A similar effect on beta-glucuronidase activity in the urine has been noted with other nephrotoxins (4) , and an elevated level of activity in urine appears to be a sensitive indicator of early rejection in patients undergoing renal homotransplantation (7) .
In experimental models of pyelonephritis, Coonrod and Paterson (5) observed that urinary beta-glucuronidase was elevated with the onset of infection and decreased with resolution of tubular injury. In their studies, both staphylococcal pyelonephritis and injections of mercuric chloride produced tubular lesions in the rat that were associated with transitory elevations in the excretion of beta-glucuronidase. Conversely 
